AstraZeneca: Calquence Combination Regimen Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in 1st-Line Mantle Cell Lymphoma in ECHO Phase III Trial
May 03, 2024
May 03, 2024
WILMINGTON, Delaware, May 3 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca's CALQUENCE(R) (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously un . . .
Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca's CALQUENCE(R) (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously un . . .